Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ondansetron · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Ondansetron HCl 24 mg Tablets (Sandoz, Inc.) |
| 2 | ACTIVE_COMPARATOR | Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline) |
| Name | Type | Description |
|---|---|---|
| Ondansetron HCl 24 mg Tablets (Sandoz, Inc.) | DRUG | - |
| Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Ondansetron is a small molecule being developed for nausea and vomiting. It is currently in Phase 1 clinical development as an investigational drug. The developer is Novartis AG, which trades under the ticker NVS.
Ondansetron is being developed by Novartis AG, a pharmaceutical company listed on the stock exchange under the ticker NVS. The drug is currently in Phase 1 clinical trials for the treatment of nausea and vomiting.
Ondansetron is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, both focusing on the bioavailability of the drug under fasting and non-fasting conditions.
Ondansetron has two completed Phase 1 clinical trials. The first, NCT00946387, studied the relative bioavailability of Ondansetron HCl 24 mg tablets under fasting conditions with 26 participants. The second, NCT00947128, studied the same under non-fasting conditions with 26 participants. Both trials involved healthy volunteers.
Ondansetron is a small molecule that works by blocking serotonin receptors in the body, which helps prevent nausea and vomiting. It is being developed for gastrointestinal conditions, specifically to treat nausea and vomiting.